Novartis stops study of iscalimab in kidney transplant patients
ZURICH (SWITZERLAND) - Novartis has halted a clinical trial of CFZ533 (iscalimab) in kidney transplant patients after ...
Read moreZURICH (SWITZERLAND) - Novartis has halted a clinical trial of CFZ533 (iscalimab) in kidney transplant patients after ...
Read moreZURICH (SWITZERLAND) - The Sandoz division of drug maker Novartis will not take a profit on ...
Read moreZURICH (Technology) - Novartis bought U.S. software start-up Amblyotech for the development of digital technology to ...
Read moreZURICH- Novartis has found alternate transport options for its cell therapy Kymriah to address potential disruptions ...
Read moreZURICH - Novartis has begun an external review after the American Society of Retinal Specialists (ASRS) ...
Read moreSwiss drugmaker Novartis AG is nearing an agreement to acquire U.S. biotechnology firm The Medicines Co ...
Read more